Stockreport

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment o...

Milestone Pharmaceuticals Inc. - Common Shares  (MIST) 
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am Check Earnings Report
PDF FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies we [Read more]